Q1 Earnings Forecast for OptimizeRx Issued By Roth Capital

OptimizeRx Co. (NASDAQ:OPRX) – Research analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of OptimizeRx in a report released on Wednesday, March 12th. Roth Capital analyst R. Baldry expects that the company will post earnings of ($0.19) per share for the quarter. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for OptimizeRx’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at $0.44 EPS.

A number of other brokerages have also recently issued reports on OPRX. Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. Stephens started coverage on OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $9.02 on Monday. The company’s 50-day moving average is $5.64 and its 200 day moving average is $5.90. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market capitalization of $166.16 million, a P/E ratio of -6.78 and a beta of 1.31. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $14.13.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently made changes to their positions in OPRX. Delta Investment Management LLC bought a new position in OptimizeRx in the fourth quarter worth $146,000. Squarepoint Ops LLC increased its holdings in shares of OptimizeRx by 298.8% during the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock valued at $203,000 after acquiring an additional 31,252 shares in the last quarter. Tang Capital Management LLC bought a new position in shares of OptimizeRx during the fourth quarter valued at $1,075,000. Graham Capital Management L.P. bought a new position in shares of OptimizeRx during the fourth quarter valued at $81,000. Finally, D. E. Shaw & Co. Inc. increased its holdings in shares of OptimizeRx by 12.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company’s stock valued at $1,437,000 after acquiring an additional 32,062 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.